Navigation Links
Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
Date:5/16/2012

PORTLAND, Ore. Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science University Knight Cancer Institute.

The study, published in the New England Journal of Medicine, found a 63 percent reduction in the risk of progressive myeloma or death for the stem cell transplant patients that were treated with lenalidomide maintenance therapy.

"These results add to the evidence that the combination of standard therapies such as stem cell transplantation with the emerging biologic therapies, like lenalidomide, have extended the lives of multiple myeloma patients," said Richard Maziarz, M.D., of the OHSU Knight Cancer Institute who was one of the study's co-authors. Maziarz serves as medical director of the Adult Stem Cell Transplantation Program & Center for Hematologic Malignancies at the OHSU Knight Cancer Institute. "We know that for at least three years following a transplant that maintenance therapy with this drug vastly improves the chances that the cancer won't come back and worsen."

These data were supported by similar Phase III studies reported from France and Italy in the same issue of the New England Jounal of Medicine demonstrating that maintenance therapy after stem cell transplantation was associated with improved disease control.

Multiple myeloma is a cancer that affects plasma cells, a type of white blood cell normally responsible for producing antibodies. In patients impacted by multiple myeloma, collections of abnormal plasma cells accumulate in the bone marrow, interfering with the production of normal blood cells. The study focused on patients who received an autologous hematopoietic cell transplant (AHCT). AHCT procedures use patients' own blood stem cells.

While lenalidomide increased a patient's ability to stave off progression of the disease, questions remain regarding future approaches recognizing that quality of life measurements were not incorporated within these studies, that long-term safety issues remain unclear as there was a small but discernable risk of second cancers observed in the treated patients. In addition to the need for that cost-benefit analysis, a comparison remains to be performed with other emerging myeloma maintenance therapies.

This Phase III study of lenalidomide was conducted at 47 medical centers and involved 568 patients. It was sponsored by the National Cancer Institute (NCI). Revlimid's manufacturer, Celgene Corp., provided the NCI with lenalidomide for this research.


'/>"/>

Contact: Elisa Williams
willieli@ohsu.edu
503-494-4530
Oregon Health & Science University
Source:Eurekalert  

Related medicine news :

1. Study urges caution with lenalidomide dosage
2. How to recognize at an early stage whether a new cancer therapy prolongs life
3. Everolimus prolongs progression-free survival for patients with neuroendocrine tumors
4. Early life stress may predict cardiovascular disease
5. Study finds racial gaps continue in heart disease awareness
6. Bowel disease link to blood clots
7. Womens Heart Disease Awareness Still Lacking
8. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
9. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
10. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
11. Alzheimers Foundation of America Applauds Social Security for Speeding Disability Benefits for Early-Onset Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... practice is offering holistic pediatric dentistry options for its patients on Long Island, ... the patient’s entire physical well being, and is one of the biggest trends ...
(Date:5/24/2017)... ... 24, 2017 , ... Technique, technique, technique – with a dash of common ... strength training and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional ... Dr. Chang says. “Improper technique in lifting anything heavy or an attempt to lift ...
(Date:5/23/2017)... ... May 23, 2017 , ... Allegheny Health Network and the ... Center for Women’s Behavioral Health at West Penn Hospital , a unique facility ... suffering from pregnancy-related depression. Construction of the Center is underway with a scheduled ...
(Date:5/23/2017)... California (PRWEB) , ... May 23, 2017 , ... ... management (PHM) technology and a 2017 Best in KLAS category winner, has named ... market position to extend and enhance its technology platform and product offerings,” says ...
(Date:5/23/2017)... ... May 23, 2017 , ... By all indications, and due ... County. While officials call for diligence, asking homeowners to scout for any open water ... concerns. Along with the annoying buzz of mosquitos is the buzz associated with potential ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/6/2017)... 2017   Provista , a proven leader in the ... today announced Jim Cunniff as the company,s new ... business experience to Provista, including most recently serving as the ... California . He assumed his new role with Provista ... fit for Provista," says Jody Hatcher , president, Sourcing ...
Breaking Medicine Technology: